Phase 3 Study of Xiaflex for Peyronie's Disease - MPR
Links shared publicly online about this topic.
- 451total visits
Phase 3 Study of Xiaflex for Peyronie's Disease - MPR
empr.com —
Auxilium announced completion of enrollment for its Phase 3 double-blind, placebo-controlled study of Xiaflex (collagenase clostridium histolyticum) for the treatment of Peyronie's Disease.
View full resource at empr.com
Tags: Disease and Condition, Phase 3 Clinical Trial, News, disease
Most Recently Shared on March 9, 2011 at 5:48 pm By:
MPR News: Phase 3 Study of Xiaflex for Peyronie's Disease: Auxilium announced completion of enrollment for its P... http://bit.ly/dYvHHm
BioSpecifics Technologies Corp. Announces Initiation Of Global Phase 3 Trial Of XIAFLEX® For Treatment Of Peyronie's Disease
medicalnewstoday.com — “BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced that its partner Auxilium Pharmaceuticals, Inc. (Auxili” View full resource at medicalnewstoday.com
Most Recently Shared on October 13, 2010 at 1:05 pm By:
BioSpecifics Technologies Corp. Announces Initiation Of Global Phase 3 Trial Of XIAFLEX® For Treatment Of Peyronie... http://mnt.to/3L7g
Advertisement
